An Open Label Study of Postmenopausal Women With Oestrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) With Exemestane, With Exploratory Epigenetic Marker Analysis

NCT01743560 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

52

Enrollment

INDUSTRY

Sponsor class

Conditions

Oestrogen Receptor Positive Advanced Breast Cancer

Interventions

DRUG: RAD001
DRUG: Exemestane

Sponsor

Novartis Pharmaceuticals